| Project/Area Number |
14370442
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
HONMOU Osamu Sapporo Medical University School of Medicine, Department of Neurosurgery, Assistant Professor, 医学部, 講師 (90285007)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAMADA Hirofumi Sapporo Medical University School of Medicine, Department of Molecular Medicine, Professor, 医学部, 教授 (00189614)
HOUKIN Kiyohiro Sapporo Medical University School of Medicine, Department of Neurosurgery, Professor, 医学部, 教授 (90229146)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥13,900,000 (Direct Cost: ¥13,900,000)
Fiscal Year 2003: ¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 2002: ¥7,200,000 (Direct Cost: ¥7,200,000)
|
|---|
| Keywords | adult / gene / human / infarction / neural stem cell / stroke / transplantation / tumor |
|---|
| Research Abstract |
Introduction : We have reported that transplantation of bone marrow cells has demonstrated therapeutic efficacy in animal models of cerebral ischemia and demyelination. In the present study, we transplanted genetically-engineering bone marrow stem cells into both middle cerebral artery occlusion model rats and brain tumor model rats, to study their potential therapeutic benefit.
Methdos : We have made three genetically-engineering bone marrow stem cells, 1)to immortalize the stem cells with hTERT gene, 2)to promote the neurotrophic effects with BDNF gene, 3)to promote the anti-tumor effect with IL=2 gene. Lesion size was assessed using MR imaging and spectroscopy, and histological methods.
Results : Transplantation of genetically-engineering bone marrow stem cells reduced lesion volume. The reduction of lesion size could be assessed in vivo with MRI and MRS and was correlated with subsequent histological examination of the brain.
Conclusion : This work demonstrates that highly purified genetically-engineering bone marrow stem cells are neuroprotective in cerebral ischemia models. Also, these cells showed the tremendous anti-tumor effects. Thus, a highly purified, expanded, and genetically-engineered cellular component of bone marrow has demonstrated the therapeutic benefits in both cerebral ischemia and brain tumor.
|
